Collectively, we show that CALR variants are genuine ERAD substrates and propose that modulations of ERAD activity could represent a therapeutic target for CALR-mutated MPN patients to attenuate CALR variant-dependent MPL activation. This evidence concerns the gene MPL and myeloproliferative disorder.